End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.6 CNY | +1.89% | -1.95% | -13.25% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.79 for the current period. Therefore, the company is undervalued.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.25% | 3.4B | C- | ||
-30.56% | 11.21B | B | ||
-30.19% | 6.23B | B | ||
+7.42% | 6B | C | ||
-10.01% | 5.89B | C+ | ||
-0.73% | 4.72B | D- | ||
+53.60% | 4.32B | - | C | |
-9.42% | 3.77B | B | ||
-5.84% | 3.03B | C- | ||
-2.20% | 2.78B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603233 Stock
- Ratings DaShenLin Pharmaceutical Group Co., Ltd.